Research progress on PD-1/PD-L1 in the treatment of non-small cell lung cancer
10.3969/j.issn.1000-8179.2017.14.159
- VernacularTitle:PD-1/PD-L1在非小细胞肺癌中的临床研究进展
- Author:
Desong YANG
;
Min SU
;
Wenxiang WANG
- Keywords:
immune therapy;
programmed death-1;
programmed death-ligand 1;
non-small cell lung cancer
- From:
Chinese Journal of Clinical Oncology
2017;44(14):726-730
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, immune therapy for the treatment of cancer has made remarkable progress. The monoclonal antibodies of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) have shown considerable responses and good tolerance in the treatment of non-small cell lung cancer (NSCLC). In this review, we summarized the current clinical status and future direction of PD-1/PD-L1 in NSCLC.
